P799: SYNERGISTIC ANTITUMOR ACTIVITY OF THE BCMA 2 + 1 T CELL ENGAGER (TCE) ALNUCTAMAB (ALNUC; BMS-986349; CC-93269) AND CELMOD AGENTS IN MULTIPLE MYELOMA (MM) PRECLINICAL MODELS

• Bruno Paiva,
• Bonny Gaffney,
• Kelven Burnett,
• Paola Castiglioni,
• Michael Angelo,
• Daniel W. Pierce,
• Isaac Boss

Affiliations

Bruno Paiva

1 Clinica Universidad de Navarra, Cancer Center Universidad de Navarra (CCUN), Centro de Investigación Medica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain

Bonny Gaffney

2 Bristol Myers Squibb, San Diego, United States

Kelven Burnett

2 Bristol Myers Squibb, San Diego, United States

Paola Castiglioni

2 Bristol Myers Squibb, San Diego, United States

Michael Angelo

2 Bristol Myers Squibb, San Diego, United States

Daniel W. Pierce

3 Bristol Myers Squibb, San Francisco, United States

Isaac Boss

4 Bristol Myers Squibb, Seattle, United States